Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822242 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3821537 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3822946 | 0.86 | PTGS2 (0.87) | PTGS2PTGS1 | |
| SCHEMBL3825944 | 0.83 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL3821955 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3820828 | 0.80 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL4575404 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL2781349 | 0.80 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL3242183 | 0.80 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL5204580 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 684 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956025-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | Allergan Sales, LLC (US) | 2022-02-23 | — | — | EP | claimed |
| US-20200383983-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | ALLERGAN SALES, LLC | 2020-12-10 | — | — | US | claimed |
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | claimed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| US-20130231311-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2013-09-05 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| US-20110118189-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2011-05-19 | — | — | US | claimed |
| WO-2001000229-A1 | COMBINATION OF TUMORS NECROCIS FACTOR (TNF) ANTAGONISTS AND COX-2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-01-04 | — | — | WO | claimed |
| EP-1061908-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2000-12-27 | — | — | EP | claimed |
| US-6136804-A | ANTIISCHEMIC AGENTS, ANTITHROMBOTIC AGENTS, THROMBOTIC OCCLUSION AND ANTIPLATELET AGENT | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | claimed |
| EP-1024696-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | Merck & Co., Inc. (US) | 2000-08-09 | — | — | EP | claimed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | claimed |
| WO-1999045913-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | claimed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | claimed |
| WO-1999020110-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | claimed |
| EP-0863134-A1 | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 | MERCK FROSST CANADA INC. (CA) | 1998-09-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | PTGS2 32/4885PTGS1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.